1675 related articles for article (PubMed ID: 16424998)
21. Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma.
Franceschi M; Kusić Z; Franceschi D; Lukinac L; Roncević S
J Nucl Med; 1996 Mar; 37(3):446-51. PubMed ID: 8772642
[TBL] [Abstract][Full Text] [Related]
22. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
[TBL] [Abstract][Full Text] [Related]
23. [Differentiated thyroid carcinoma, 1972-1992. Follow-up, detection of recurrences and prognostic factors].
Obiols G; Simó R; Burgos R; Tresserras R; Galofré P; Masmiquel L; Hernández C; Mesa J
Med Clin (Barc); 1997 Nov; 109(19):738-43. PubMed ID: 9470182
[TBL] [Abstract][Full Text] [Related]
24. Thyroperoxidase: a tumor marker for post-therapeutic follow-up of differentiated thyroid carcinomas? Results of a time course study.
Franke WG; Zöphel K; Wunderlich GR; Mat R; Kühne A; Schimming C; Kropp J; Bredow J
Cancer Detect Prev; 2000; 24(6):524-30. PubMed ID: 11198265
[TBL] [Abstract][Full Text] [Related]
25. Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer.
Kovatcheva RD; Hadjieva TD; Kirilov GG; Lozanov BS
Nucl Med Rev Cent East Eur; 2004; 7(1):13-9. PubMed ID: 15318305
[TBL] [Abstract][Full Text] [Related]
26. Charcoal suspension tattoo localization for differentiated thyroid cancer recurrence.
Hartl DM; Chami L; Al Ghuzlan A; Leboulleux S; Baudin E; Schlumberger M; Travagli JP
Ann Surg Oncol; 2009 Sep; 16(9):2602-8. PubMed ID: 19551443
[TBL] [Abstract][Full Text] [Related]
27. [Radioiodine therapy for thyroid cancer].
Misaki T
Nihon Rinsho; 2007 Nov; 65(11):2049-52. PubMed ID: 18018569
[TBL] [Abstract][Full Text] [Related]
28. Differentiated thyroid cancer: clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases. A report from the Surgical Discipline Committee of the Children's Cancer Group.
La Quaglia MP; Black T; Holcomb GW; Sklar C; Azizkhan RG; Haase GM; Newman KD
J Pediatr Surg; 2000 Jun; 35(6):955-9; discussion 960. PubMed ID: 10873043
[TBL] [Abstract][Full Text] [Related]
29. [Differentiated thyroid carcinoma in childhood].
Visa Zueras MT; Alonso Blanco M; Yturriaga Matarranz R; Ros Pérez P; Monroy Morante C; Sarriá Oses JM; Barrio Castellanos R
An Esp Pediatr; 1992 Jul; 37(1):11-4. PubMed ID: 1416515
[TBL] [Abstract][Full Text] [Related]
30. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F
Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic outcomes of papillary thyroid carcinomas with tumors more advanced than T1N0M0.
Lin JD; Lin KJ; Chao TC; Hseuh C; Tsang NM
Radiother Oncol; 2008 Oct; 89(1):97-104. PubMed ID: 18534700
[TBL] [Abstract][Full Text] [Related]
32. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis, treatment, prognostic factors and long-term outcome in papillary thyroid carcinoma.
Pelizzo MR; Merante Boschin I; Toniato A; Pagetta C; Casal Ide E; Mian C; Rubello D
Minerva Endocrinol; 2008 Dec; 33(4):359-79. PubMed ID: 18923371
[TBL] [Abstract][Full Text] [Related]
34. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
35. Papillary thyroid microcarcinoma: a surgical perspective.
Sakorafas GH; Giotakis J; Stafyla V
Cancer Treat Rev; 2005 Oct; 31(6):423-38. PubMed ID: 16005155
[TBL] [Abstract][Full Text] [Related]
36. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
[TBL] [Abstract][Full Text] [Related]
37. [Radioiodine therapy in differentiated thyroid gland carcinoma].
Schicha H; Dietlein M
Zentralbl Chir; 1997; 122(4):266-73. PubMed ID: 9221637
[TBL] [Abstract][Full Text] [Related]
38. Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma.
Frilling A; Görges R; Tecklenborg K; Gassmann P; Bockhorn M; Clausen M; Broelsch CE
Surgery; 2000 Dec; 128(6):1067-74. PubMed ID: 11114644
[TBL] [Abstract][Full Text] [Related]
39. Role of 131I in the treatment of well differentiated thyroid cancer.
Woodrum DT; Gauger PG
J Surg Oncol; 2005 Mar; 89(3):114-21. PubMed ID: 15719384
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the diagnostic value of the first thyroglobulin determination in detecting metastases after differentiated thyroid carcinoma surgery.
Makarewicz J; Adamczewski Z; Knapska-Kucharska M; Lewiński A
Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):485-9. PubMed ID: 17115345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
